Edwards Lifesciences Corp. Stock Underperforms Thursday When Compared To Competitors

Dow Jones11-01

DJ Edwards Lifesciences Corp. Stock Underperforms Thursday When Compared To Competitors

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Edwards Lifesciences Corp. $(EW)$ slipped 2.36% to $67.01 Thursday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index falling 1.86% to 5,705.45 and Dow Jones Industrial Average falling 0.90% to 41,763.46.

This was the stock's second consecutive day of losses.

Edwards Lifesciences Corp. closed $29.11 below its 52-week high ($96.12), which the company achieved on March 28th.

The stock underperformed when compared to some of its competitors Thursday, as Abbott Laboratories $(ABT)$ fell 0.94% to $113.37, Medtronic PLC $(MDT)$ fell 1.38% to $89.25, and Stryker Corp. $(SYK)$ fell 1.97% to $356.28.

Trading volume (6.3 M) remained 138,514 below its 50-day average volume of 6.4 M.

Data source: Dow Jones Market Data, FactSet. Data compiled October 31, 2024.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

 

(END) Dow Jones Newswires

October 31, 2024 16:56 ET (20:56 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment